<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04560816</url>
  </required_header>
  <id_info>
    <org_study_id>ALXN1840-HV-107</org_study_id>
    <nct_id>NCT04560816</nct_id>
  </id_info>
  <brief_title>A Study of the Cardiac Effects of ALXN1840 in Healthy Adults</brief_title>
  <official_title>A Randomized, Three-Treatment, Three-Period, Six-Sequence, Crossover, Placebo- and Active-Controlled, Double-Blind for ALXN1840 (Open-Label for Moxifloxacin) Thorough QT/QTc (TQT) Study to Evaluate the Effect of ALXN1840 on Cardiac Repolarization in Healthy Adult Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexion Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>PPD</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>ERT: Clinical Trial Technology Solutions</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Alexion Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the effect of a supratherapeutic dose of ALXN1840 on the heart rate&#xD;
      (HR)-corrected QT interval (QTc) in healthy adult participants. Moxifloxacin will be used as&#xD;
      the active control.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, 3-treatment, 3-period, 6-sequence, crossover, placebo- and&#xD;
      active-controlled, double-blind for ALXN1840, open-label for moxifloxacin, in healthy adult&#xD;
      participants. Participants will be domiciled in the clinic for 7 days during Treatment Period&#xD;
      1 and for 6 days during Treatment Period 2 and 3. A single oral dose of each treatment&#xD;
      (ALXN1840, matching ALXN1840 placebo, or moxifloxacin) will be administered on Day 1 of each&#xD;
      period following an overnight fast of at least 10 hours. There will be a minimum 14-day&#xD;
      washout between study intervention administrations for each treatment period. Cardiodynamic,&#xD;
      pharmacokinetic, and safety assessments will be performed at certain times during the study.&#xD;
      An end-of-study visit will occur 14 days (±2 days) after the last dose.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">July 24, 2020</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>This will be a 3-treatment, 3-period, 6-sequence, crossover study in healthy adults.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
    <masking_description>This study will employ a double-blind study design. The ALXN1840 and matching placebo will be identical in appearance and will be administered in a double-blind manner.&#xD;
Moxifloxacin will not be blinded.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Placebo-corrected Change From Baseline QTc For ALXN1840 Using The By-time Point Analysis</measure>
    <time_frame>Pre-dose through 24 hours post-dose</time_frame>
    <description>Twelve-lead electrocardiograms (ECGs) will be extracted from approximately 25-hour continuous (Holter) recordings on Day -1 of Treatment Period 1 and Days 1 and 2 in each treatment period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline ΔΔQTcF For Moxifloxacin Using The By-time Point Analysis</measure>
    <time_frame>Pre-dose through 24 hours post-dose</time_frame>
    <description>Twelve-lead ECGs will be extracted from approximately 25-hour continuous (Holter) recordings on Day -1 of Treatment Period 1 and Days 1 and 2 in each treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline Heart Rate (ΔHR) For ALXN1840</measure>
    <time_frame>Baseline, 24 hours postdose</time_frame>
    <description>Twelve-lead ECGs will be extracted from approximately 25-hour continuous (Holter) recordings on Day -1 of Treatment Period 1 and Days 1 and 2 in each treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline PR Interval (ΔPR) For ALXN1840</measure>
    <time_frame>Baseline, 24 hours postdose</time_frame>
    <description>Twelve-lead ECGs will be extracted from approximately 25-hour continuous (Holter) recordings on Day -1 of Treatment Period 1 and Days 1 and 2 in each treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline QRS Interval (ΔQRS) For ALXN1840</measure>
    <time_frame>Baseline, 24 hours postdose</time_frame>
    <description>Twelve-lead ECGs will be extracted from approximately 25-hour continuous (Holter) recordings on Day -1 of Treatment Period 1 and Days 1 and 2 in each treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Placebo-corrected Change From Baseline Heart Rate (ΔΔHR) For ALXN1840</measure>
    <time_frame>Baseline, 24 hours postdose</time_frame>
    <description>Twelve-lead ECGs will be extracted from approximately 25-hour continuous (Holter) recordings on Day -1 of Treatment Period 1 and Days 1 and 2 in each treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Placebo-corrected Change From Baseline PR Interval (ΔΔPR) For ALXN1840</measure>
    <time_frame>Baseline, 24 hours postdose</time_frame>
    <description>Twelve-lead ECGs will be extracted from approximately 25-hour continuous (Holter) recordings on Day -1 of Treatment Period 1 and Days 1 and 2 in each treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Placebo-corrected Change From Baseline QRS Interval (ΔΔQRS) For ALXN1840</measure>
    <time_frame>Baseline, 24 hours postdose</time_frame>
    <description>Twelve-lead ECGs will be extracted from approximately 25-hour continuous (Holter) recordings on Day -1 of Treatment Period 1 and Days 1 and 2 in each treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-emergent T-wave Morphology Abnormalities And U-waves</measure>
    <time_frame>Day 1 (after dosing) through 24 hours postdose</time_frame>
    <description>Twelve-lead ECGs will be extracted from approximately 25-hour continuous (Holter) recordings on Day -1 of Treatment Period 1 and Days 1 and 2 in each treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under The Concentration Versus Time Curve From Time 0 To The Last Quantifiable Concentration (AUC0-t) Of Total Molybdenum And Plasma Ultrafiltrate Molybdenum</measure>
    <time_frame>Baseline, up to 96 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Concentration (Cmax) Of Total Molybdenum And Plasma Ultrafiltrate Molybdenum</measure>
    <time_frame>Baseline, up to 96 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time To Maximum Observed Concentration (Tmax) Of Total Molybdenum And Plasma Ultrafiltrate Molybdenum</measure>
    <time_frame>Baseline, up to 96 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence Of Treatment-emergent Adverse Events</measure>
    <time_frame>Day 1 (after dosing) through Day 70</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Treatment Sequence 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>On Day 1 of each period, participants will receive a single dose of the following study interventions:&#xD;
Period 1: ALXN1840.&#xD;
Period 2: Placebo-matching ALXN1840.&#xD;
Period 3: Moxifloxacin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Sequence 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>On Day 1 of each period, participants will receive a single dose of the following study interventions:&#xD;
Period 1: ALXN1840.&#xD;
Period 2: Moxifloxacin.&#xD;
Period 3: Placebo-matching ALXN1840.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Sequence 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>On Day 1 of each period, participants will receive a single dose of the following study interventions:&#xD;
Period 1: Placebo-matching ALXN1840.&#xD;
Period 2: ALXN1840.&#xD;
Period 3: Moxifloxacin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Sequence 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>On Day 1 of each period, participants will receive a single dose of the following study interventions:&#xD;
Period 1: Placebo-matching ALXN1840.&#xD;
Period 2: Moxifloxacin.&#xD;
Period 3: ALXN1840.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Sequence 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>On Day 1 of each period, participants will receive a single dose of the following study interventions:&#xD;
Period 1: Moxifloxacin.&#xD;
Period 2: ALXN1840.&#xD;
Period 3: Placebo-matching ALXN1840.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Sequence 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>On Day 1 of each period, participants will receive a single dose of the following study interventions:&#xD;
Period 1: Moxifloxacin.&#xD;
Period 2: Placebo-matching ALXN1840.&#xD;
Period 3: ALXN1840.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALXN1840</intervention_name>
    <description>ALXN1840 (120 milligrams) will be administered orally (supratherapeutic dose).</description>
    <arm_group_label>Treatment Sequence 1</arm_group_label>
    <arm_group_label>Treatment Sequence 2</arm_group_label>
    <arm_group_label>Treatment Sequence 3</arm_group_label>
    <arm_group_label>Treatment Sequence 4</arm_group_label>
    <arm_group_label>Treatment Sequence 5</arm_group_label>
    <arm_group_label>Treatment Sequence 6</arm_group_label>
    <other_name>WTX101</other_name>
    <other_name>Bis-choline tetrathiomolybdate</other_name>
    <other_name>Tiomolibdate choline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be administered orally.</description>
    <arm_group_label>Treatment Sequence 1</arm_group_label>
    <arm_group_label>Treatment Sequence 2</arm_group_label>
    <arm_group_label>Treatment Sequence 3</arm_group_label>
    <arm_group_label>Treatment Sequence 4</arm_group_label>
    <arm_group_label>Treatment Sequence 5</arm_group_label>
    <arm_group_label>Treatment Sequence 6</arm_group_label>
    <other_name>Placebo-matching ALXN1840</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin</intervention_name>
    <description>Moxifloxacin (400 milligrams) will be administered orally.</description>
    <arm_group_label>Treatment Sequence 1</arm_group_label>
    <arm_group_label>Treatment Sequence 2</arm_group_label>
    <arm_group_label>Treatment Sequence 3</arm_group_label>
    <arm_group_label>Treatment Sequence 4</arm_group_label>
    <arm_group_label>Treatment Sequence 5</arm_group_label>
    <arm_group_label>Treatment Sequence 6</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Nonsmoker.&#xD;
&#xD;
          2. Body weight at least 60 kilograms (kg) for males or 52 kg for females and body mass&#xD;
             index ≥18.0 and ≤30.0 kg/meter squared.&#xD;
&#xD;
          3. Willing and able to follow protocol-specified contraception requirements.&#xD;
&#xD;
          4. Participant has no clinically significant history or presence of ECG findings.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History or presence of clinical and/or lab disorders.&#xD;
&#xD;
          2. Lymphoma, leukemia, or any malignancy within the past 5 years, or breast cancer within&#xD;
             the past 10 years.&#xD;
&#xD;
          3. Participant has abnormal blood pressure, defined as a supine blood pressure &lt;90/50&#xD;
             millimeters of mercury (mm Hg) or &gt;140/90 mm Hg.&#xD;
&#xD;
          4. Serum potassium, calcium, or magnesium levels outside the normal range.&#xD;
&#xD;
          5. Serum copper and/or ceruloplasmin values below the lower limit of normal at Screening.&#xD;
&#xD;
          6. Female participant has hemoglobin &lt;10.8 grams/deciliter (g/dL) and male participant&#xD;
             has hemoglobin &lt;12.5 g/dL.&#xD;
&#xD;
          7. Clinically significant multiple or severe allergies.&#xD;
&#xD;
          8. Alanine aminotransferase, aspartate aminotransferase, serum creatinine, or total&#xD;
             bilirubin greater than upper limit of normal (with the exception of Gilbert's&#xD;
             syndrome).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78744</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>September 18, 2020</study_first_submitted>
  <study_first_submitted_qc>September 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 23, 2020</study_first_posted>
  <last_update_submitted>February 11, 2021</last_update_submitted>
  <last_update_submitted_qc>February 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Electrocardiogram</keyword>
  <keyword>Cardiac Repolarization</keyword>
  <keyword>ALXN1840</keyword>
  <keyword>Optimized QT Correction</keyword>
  <keyword>QT Interval Correction</keyword>
  <keyword>Thorough QT</keyword>
  <keyword>QT Correction by Fridericia</keyword>
  <keyword>Individual QT Correction</keyword>
  <keyword>Wilson Disease</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Tetrathiomolybdate</mesh_term>
    <mesh_term>Choline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

